Delavirdine Susceptibilities and Associated Reverse Transcriptase Mutations in Human Immunodeficiency Virus Type 1 Isolates from Patients in a Phase I/II Trial of Delavirdine Monotherapy (ACTG 260)-Reference-Cited by-同舟云学术

Delavirdine Susceptibilities and Associated Reverse Transcriptase Mutations in Human Immunodeficiency Virus Type 1 Isolates from Patients in a Phase I/II Trial of Delavirdine Monotherapy (ACTG 260)

Published:2000-03 Issue:3 Volume:44 Page:794-797
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Demeter L. M.¹,Shafer R. W.²,Meehan P. M.³,Holden-Wiltse J.³,Fischl M. A.⁴,Freimuth W. W.⁵,Para M. F.⁶,Reichman R. C.¹

Affiliation:

1. University of Rochester School of Medicine and Dentistry, Rochester, New York1;

2. Stanford University, Palo Alto, California2;

3. Harvard School of Public Health, Boston, Massachusetts3;

4. University of Miami, Miami, Florida4;

5. Pharmacia and Upjohn, Kalamazoo, Michigan5; and

6. Ohio State University, Columbus, Ohio6

Abstract

ABSTRACT The development of human immunodeficiency virus type 1 resistance to delavirdine (DLV) was studied in subjects receiving DLV monotherapy. Phenotypic resistance developed in 28 of 30 subjects within 8 weeks. K103N and Y181C, which confer nonnucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance, were the predominant reverse transcriptase mutations. P236L, which confers DLV resistance but hypersensitivity to other NNRTIs, developed in <10% of isolates.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.44.3.794-797.2000

Reference19 articles.

1. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors

2. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development.;de Clercq E.;Med. Res. Rev.,1996

3. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.;Demeter L. M.;J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.,1997

4. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication

5. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors.;Dueweke T. J.;Proc. Natl. Acad. Sci. USA,1993

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence and Phenotypic Susceptibility to Doravirine of the HIV-1 Reverse Transcriptase V106I Polymorphism in B and Non-B Subtypes;The Journal of Infectious Diseases;2024-01-11

2. Towards Rare-Functionalized N-Alkenyl-1H-pyrroles via Regioselectively Metalated N-Isopropenyl-1H-pyrroles;Synthesis;2022-01-11

3. 2-methylindole analogs as cholinesterases and glutathione S-transferase inhibitors: Synthesis, biological evaluation, molecular docking, and pharmacokinetic studies;Arabian Journal of Chemistry;2021-12

4. The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic;Journal of Medicinal Chemistry;2018-12-05

5. PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection;HIV Clinical Trials;2018-04-20